世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

カンナビジオール市場の規模、シェア、動向分析レポート:ソースタイプ別(麻、マリファナ)、流通チャネル別(B2B、B2C)、エンドユーザー別(医療、個人使用)、地域別、セグメント別予測、2022年~2030年


Cannabidiol Market Size, Share & Trends Analysis Report By Source Type (Hemp, Marijuana), By Distribution Channel (B2B, B2C), By End-use (Medical, Personal Use), By Region, And Segment Forecasts, 2022 - 2030

カンナビジオール市場の成長・トレンド Grand View Research, Inc.の新しい調査によると、カンナビジオールの世界市場規模は2030年までに220億5000万米ドルに達すると予測されています。同市場は2022年から203... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2022年5月20日 US$5,950
シングルユーザーライセンス
ライセンス・価格情報
注文方法はこちら
132 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

カンナビジオール市場の成長・トレンド

Grand View Research, Inc.の新しい調査によると、カンナビジオールの世界市場規模は2030年までに220億5000万米ドルに達すると予測されています。同市場は2022年から2030年にかけて年平均成長率16.8%で拡大する見通しです。カンナビジオール(CBD)の健康効果に関する意識の高まり、消費者の意見の変化、CBD製品に対する姿勢などが、これらの製品の需要を促進する主な要因の一部となっています。カンナビジオールは、大麻サティバ植物に含まれる化学化合物であり、麻または大麻から抽出されますが、一般的にはCBD含有量が自然に高いため、麻から抽出されます。大麻サティバ植物には、カンナビノイドとして識別される80以上の化学物質があります。すべての化学物質のうち、カンナビジオールは精神作用がないため、医療用として最も広く使用されています。

カンナビジオールオイルは、不安やうつなどの疾患の治療のほか、ストレス緩和、がんの症状緩和、炎症、糖尿病予防など、さまざまな医療用途に使用されています。近年のCOVID-19の大流行は、CBD業界を含む世界中の多くの産業に影響を及ぼしています。COVID-19の影響により、生産工程に混乱が生じました。世界中で厳しい検疫措置が取られているため、CBD製品を含む製品の供給が滞っています。また、現在、パンデミックのため、小売店のほとんどが閉店しています。したがって、市場はパンデミックの中で減速に直面する可能性がありますが、今後数年間でCBDベースの製品の需要が増加するため、2021年に勢いを得ることができます。

世界市場は、病気を治療するためのCBDベースの製品の受け入れが増加しているため、予測期間中に有利な速度で発展することが期待されます。フィットネスの目標を達成し、炎症や痛みなどの問題を回避するために、栄養豊富な食品に対するニーズが高まっています。さらに、食品安全センター(CFS)は、CBDベースの製品を販売する企業を、その製造プロセス、加工手順、試験プロセス、および顧客の開放性に基づいて評価します。このような政府の活動が消費者の関心を呼び、結果としてCBDベースの製品の取り込みが進みました。

CBD入り商品の導入は、業界の大手企業にとって優先事項となっています。CBDオイルは、非精神作用で合法的な麻の成分であり、食品、健康製品、医薬品、化粧品など、さまざまな産業で使用することができます。CBD市場で大きな収益シェアを獲得するために、業界プレーヤーは合併、買収、新製品導入などの有機的および無機的な方法を使用することが予想されます。2021年6月、バーティカルウェルネスは、カナダを拠点にヘンプに関する複数の製品・サービスを提供するCanaFarma Hemp Products Corp.と合併することに合意したと発表しました。合併後、米国を拠点とするカンナビジオール企業であるバーティカル・ウェルネスは、合計5,000万米ドルの価値を持つ公的企業に変身することになる。

カンナビジオール市場レポートハイライト

- 北米は2021年に最大の収益シェアを占め、予測期間中もそのリードを維持すると予想されます。有利な規制、CBDオイルに関する認知度の向上、消費者の嗜好の高まり、メーカー数の増加が、同地域の市場成長を促進する要因として期待される

- 2021年には、マリファナ由来のカンナビジオールを注入した製品の健康効果に関する認知度の上昇により、ヘンプソースタイプのセグメントが予測期間中に最も早いCAGRを記録すると予想されます。また、さまざまな国でヘンプの合法化が進んでいることも、重要な成長要因です。

- B2B流通チャネルは、カンナビジオールを原料として使用する企業の増加や需要の増加により、2021年に最大の売上高シェアを占めました。健康とウェルネス、医薬品、食品と添加物、化粧品などの様々な分野でカンナビジオール製品の需要が増加しているため、企業は自社製品のためにカンナビジオール原料または前駆物質を一括で調達する必要性が高まっています。したがって、様々な成長機会は、このセグメントの成長を促進することが期待されるカンナビジオール卸売事業で浮上している

- 2021年、医療用エンドユーズセグメントは、様々な医療条件のための大麻誘導体の使用の上昇に起因する最大の収益シェアを占めた。

ページTOPに戻る


目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.3.1 Region Market: CAGR Calculation
1.4 Region Based Segment Share Calculation
1.5 List of Secondary Sources
1.6 List of Primary Sources
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 CBD Market Variables, Trends & Scope
3.1 Market Segmentation (Global Cannabidiol (CBD) Market)
3.2 Global Cannabis Extracts Trade Route
3.3 Global Cannabis Extracts Demand and Supply Analysis
3.4 Penetration & Growth Prospects Mapping
3.5 Cannabis Regulatory Scenario, By Country
3.5.1 U.S.
3.5.1.1 Cultivation/Production
3.5.1.2 Legal Status (CBD & THC)
3.5.1.3 Regulatory Bodies Involved
3.5.2 Canada
3.5.2.1 Cultivation
3.5.2.2 Production
3.5.2.3 Legal Status (CBD & THC)
3.5.2.4 Regulatory Bodies Involved
3.5.3 Germany
3.5.3.1 Cultivation/Production
3.5.3.2 Legal Status (CBD & THC)
3.5.3.3 Regulatory Bodies Involved
3.5.4 Italy
3.5.4.1 Cultivation
3.5.4.2 Production
3.5.4.3 Legal Status (CBD & THC)
3.5.4.4 Regulatory Bodies Involved
3.5.5 Croatia
3.5.5.1 Cultivation/Production
3.5.5.2 Legal Status (CBD & THC)
3.5.5.3 Regulatory Bodies Involved
3.5.6 Netherlands
3.5.6.1 Cultivation
3.5.6.2 Production
3.5.6.3 Legal Status (CBD & THC)
3.5.6.4 Regulatory Bodies Involved
3.5.7 Czech Republic
3.5.7.1 Cultivation/Production
3.5.7.2 Legal Status (CBD & THC)
3.5.8 Poland
3.5.8.1 Cultivation/Production
3.5.8.2 Legal Status (CBD & THC)
3.5.8.3 Regulatory Bodies Involved
3.5.9 Switzerland
3.5.9.1 Cultivation/Production
3.5.9.2 Legal Status (CBD & THC)
3.5.9.3 Regulatory Bodies Involved
3.5.10 Australia
3.5.10.1 Cultivation/Production
3.5.10.2 Legal Status (CBD & THC)
3.5.10.3 Regulatory Bodies Involved
3.5.11 Israel
3.5.11.1 Cultivation/Production
3.5.11.2 Legal Status (CBD & THC)
3.5.11.3 Regulatory Bodies Involved
3.5.12 Ururguay
3.5.12.1 Cultivation/Production
3.5.12.2 Legal Status (CBD & THC)
3.5.12.3 Regulatory Bodies Involved
3.5.13 Colombia
3.5.13.1 Cultivation/Production
3.5.13.2 Legal Status (CBD & THC)
3.5.13.3 Regulatory Bodies Involved
3.5.14 Argentina
3.5.14.1 Cultivation/Production
3.5.14.2 Legal Status (CBD & THC)
3.5.14.3 Regulatory Bodies Involved
3.5.15 Chile
3.5.15.1 Cultivation/Production
3.5.15.2 Legal Status (CBD & THC)
3.5.15.3 Regulatory Bodies Involved
3.6 Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Growing legalization of cannabis-based CBD products
3.6.1.2 Increasing preference toward cannabis extracts such as oils and tinctures
3.6.1.3 Growing adoption of CBD-based products for treating various medical conditions
3.6.1.4 Rise in the number of retailers selling CBD-based products
3.6.2 Market Restraint Analysis
3.6.2.1 Stringent government regulations
3.6.2.2 Absence of legalization programs in several Asian and African countries
3.6.2.3 High cost of CBD in leading markets
3.6.3 Industry Challenges
3.7 Cannabidiol (CBD) - Porter’s Analysis
3.7.1 Threat of New Entrants
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Bargaining Power of Suppliers
3.7.5 Threat of Substitutes
3.8 Cannabidiol (CBD) - PESTEL Analysis
3.8.1 Political
3.8.2 Environmental
3.8.3 Social
3.8.4 Technology
3.8.5 Legal
3.8.6 Economic
3.9 Opportunity Analysis
3.10 Import/Export Scenario, by Country
3.10.1 U.S.
3.10.2 Canada
3.10.2.1 Import
3.10.2.2 Export
3.10.3 Germany
3.10.4 Italy
3.10.5 France
3.10.6 Croatia
3.10.7 Netherlands
3.10.8 Czech Republic
3.10.9 Poland
3.10.10 Switzerland
3.10.11 Uruguay
3.10.12 Columbia
3.10.13 Brazil
3.10.14 Argentina
3.10.15 Chile
3.10.16 Australia
3.10.17 China
3.10.18 India
3.10.19 Japan
3.10.20 New Zealand
3.10.21 South Korea
3.10.22 South Africa
3.10.23 Israel
3.11 Product Adoption Pattern Analysis
3.12 Value Chain Analysis
3.12.1 Raw Material Trends
3.12.1.1 Market price evolution of biomass commodity cost (to processor)
3.12.1.2 Manufacturing Trends
3.13 Average Selling Price of Cannabidiol, by Country
3.14 Key End Users
3.14.1 U.S. Market Scenario
3.15 COVID-19 Impact Analysis
Chapter 4 Cannabidiol (CBD) Market: Source Type Estimates & Trend Analysis
4.1 Cannabidiol (CBD) Market Size & Forecasts And Trend Analysis By Source Type, 2017 - 2030, (USD Million)
4.1.1 Hemp
4.1.1.1 Hemp CBD market estimates and forecasts, 2017 - 2030 (USD Million)
4.1.2 Marijuana
4.1.2.1 Marijuana CBD market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 5 Cannabidiol (CBD) Market: Distribution Channel Estimates & Trend Analysis
5.1 Cannabidiol (CBD) Market, By Distribution Channel Analysis
5.2 Business to Business (B2B)
5.2.1 Business to Business (B2B) market estimates and forecasts, 2017 - 2030 (USD Million)
5.3 Business to Consumer (B2C)
5.3.1 Hospital Pharmacies
5.3.1.1 Hospital pharmacies market estimates and forecasts, 2017 - 2030 (USD Million)
5.3.2 Online Stores
5.3.2.1 Online market estimates and forecasts, 2017 - 2030 (USD Million)
5.3.3 Retail Stores
5.3.3.1 Retail stores market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 6 Cannabidiol (CBD) Market: End-use Estimates & Trend Analysis
6.1 Cannabidiol (CBD) Market, By End-use Analysis
6.2 Medical
6.2.1 Chronic Pain
6.2.1.1 Chronic pain market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.2 Mental Disorders
6.2.2.1 Mental disorders market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.3 Cancer
6.2.3.1 Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.4 Others
6.2.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
6.3 Personal Use
6.3.1 Personal Use market estimates and forecasts, 2017 - 2030 (USD Million)
6.4 Pharmaceutical
6.4.1 Pharmaceutical CBD market estimates and forecasts, 2017 - 2030 (USD Million)
6.5 Wellness
6.5.1 Food & Beverages
6.5.1.1 Food & beverages market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.2 Personal Care & Cosmetics
6.5.2.1 Personal care & cosmetics market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.3 Nutraceuticals
6.5.3.1 Nutraceuticals market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.4 Others
6.5.4.1 Other end-use market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 7 Cannabidiol (CBD) Market: Regional Estimates & Trend Analysis
7.1 Global Cannabidiol Market Share, By Region, 2021 & 2030
7.2 North America
7.2.1 U.S.
7.2.1.1 U.S. CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.2.2 Canada
7.2.2.1 Canada CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3 Europe
7.3.1 U.K.
7.3.1.1 U.K. CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.2 Germany
7.3.2.1 Germany CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.3 France
7.3.3.1 France CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.4 Italy
7.3.4.1 Italy CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.5 Netherlands
7.3.5.1 Netherlands CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.6 Croatia
7.3.6.1 Croatia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.7 Poland
7.3.7.1 Poland CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.8 Czech Republic
7.3.8.1 Czech Republic CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.9 Switzerland
7.3.9.1 Switzerland CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Australia
7.4.1.1 Australia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China CBD Market market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.3 India
7.4.3.1 India CBD Market market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.5 New Zealand
7.4.5.1 New Zealand CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5 Latin America
7.5.1 Brazil
7.5.1.1 Brazil CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.2 Argentina
7.5.2.1 Argentina CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.3 Colombia
7.5.3.1 Colombia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.4 Mexico
7.5.4.1 Mexico CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.5 Uruguay
7.5.5.1 Uruguay CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.6 Chile
7.5.6.1 Chile CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.6 MEA
7.6.1 South Africa
7.6.1.1 South Africa CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.6.2 Israel
7.6.2.1 Israel CBD market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Company Profiles (Cannabis Companies)
8.1.1 Canopy Growth Corporation.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.2 Product Benchmarking
8.1.2.1 Strategic Initiatives
8.1.3 Aphria, Inc.
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 Aurora Cannabis
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Strategic initiatives
8.1.5 Maricann, Inc. (Wayland Group Corporation)
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Business strategies
8.1.6 Tilray
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Strategic Initiatives
8.1.7 GW Pharmaceuticals, plc
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Strategic Initiatives
8.1.8 ABcann Medicinals, Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Strategic Initiatives
8.1.9 Organigram Holding, Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Strategic Initiatives
8.1.10 Tikun Olam
8.1.10.1 Company overview
8.1.10.2 Strategic Initiatives
8.1.11 The Cronos Group
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Strategic Initiatives
8.2 Company Profiles (Cannabidiol Companies)
8.2.1 ENDOCA
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Isodiol International, Inc.
8.2.2.1 Company overview
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.3 MEDICAL MARIJUANA, INC.
8.2.3.1 company overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 Cannoid, LLC
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.5 Elixinol
8.2.5.1 Company Overview
8.2.5.2 Product Benchmarking
8.2.5.3 Strategic Initiatives
8.2.6 Folium Biosciences
8.2.6.1 Company Overview
8.2.6.2 Product Benchmarking
8.2.6.3 Strategic Initiatives
8.2.7 NuLeaf Naturals, LLC
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Pharmahemp d.o.o.
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking

 

ページTOPに戻る


 

Summary

Cannabidiol Market Growth & Trends

The global cannabidiol market size is expected to reach USD 22.05 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.8% from 2022 to 2030. Increasing awareness regarding the health benefits of cannabidiol (CBD), changing consumer opinion, and the attitude toward CBD products are some of the key factors driving the demand for these products. Cannabidiol is a chemical compound that is found in the cannabis Sativa plant, and is extracted from hemp or cannabis, generally from hemp due to its naturally high CBD content. The cannabis Sativa plant has over 80 chemicals that are identified as cannabinoids. Out of all the chemicals, cannabidiol is most widely used for medical purposes due to its lack of psychoactive effect.

Cannabidiol oil is used in various medical applications to treat disorders including anxiety and depression and is also used for stress relief, cancer symptom relief, inflammation, and diabetes prevention. The recent COVID-19 pandemic has affected many industries around the world, including the CBD industry. The impact of COVID-19 has led to disruption in production processes. Due to strict quarantine measures taken across the globe, there is a stagnation in the supply of products, including CBD products. In addition, most of the retail stores are currently closed due to the pandemic. Hence, the marketplace may face a slowdown amidst the pandemic, however, it can gain momentum in 2021 due to the increase in demand for CBD-based products in the coming years.

The global market is expected to develop at a lucrative rate over the forecast period owing to the increased acceptance of CBD-based products to treat diseases. There is a growing need for nutrient-rich foods to help people achieve fitness objectives and avoid problems such as inflammation and pain. Furthermore, the Center for Food Safety (CFS) assesses companies that sell CBD-based products based on their manufacturing process, processing procedures, testing processes, and customer openness. Such government activities piqued consumer interest, resulting in increased uptake of CBD-based products.

The introduction of CBD-infused goods is a priority for major industry players. CBD oil is a non-psychoactive and legal component of hemp that can be used in a variety of industries, including food, health products, pharmaceuticals, and cosmetics. To capture a large revenue share in the CBD market, the industry players are expected to use organic and inorganic methods such as mergers, acquisitions, and new product introduction. In June 2021, Vertical Wellness announced that it has agreed to merge with CanaFarma Hemp Products Corp., a Canada-based company that offers multiple products and services related to hemp. After the merger, Vertical Wellness, a U.S.-based cannabidiol company, would transform into a public entity with a combined worth of USD 50 million.

Cannabidiol Market Report Highlights

• North America accounted for the largest revenue share in 2021 and is expected to maintain its lead over the forecast period. Favorable regulations, increasing awareness about CBD oil, growing consumer preference, and a rise in the number of manufacturers are the factors expected to fuel market growth in the region

• In 2021, the hemp source type segment is expected to register the fastest CAGR over the forecast period owing to the rising awareness regarding the health benefits of products infused with cannabidiol derived from marijuana. The increasing legalization of hemp in various countries is also a key growth factor

• The B2B distribution channel segment accounted for the largest revenue share in 2021 owing to the increasing demand and rising number of businesses using cannabidiol as raw materials. Growing demand for cannabidiol products in various sectors such as health and wellness, pharmaceutical, food and additives, and cosmetics has increased the need for companies to procure cannabidiol raw material or precursor material for their products in bulk. Hence, various growth opportunities are emerging in the cannabidiol wholesale business, which is expected to propel the growth of this segment

• In 2021, the medical end-use segment accounted for the largest revenue share owing to the rising use of cannabis derivatives for various medical conditions



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.3.1 Region Market: CAGR Calculation
1.4 Region Based Segment Share Calculation
1.5 List of Secondary Sources
1.6 List of Primary Sources
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 CBD Market Variables, Trends & Scope
3.1 Market Segmentation (Global Cannabidiol (CBD) Market)
3.2 Global Cannabis Extracts Trade Route
3.3 Global Cannabis Extracts Demand and Supply Analysis
3.4 Penetration & Growth Prospects Mapping
3.5 Cannabis Regulatory Scenario, By Country
3.5.1 U.S.
3.5.1.1 Cultivation/Production
3.5.1.2 Legal Status (CBD & THC)
3.5.1.3 Regulatory Bodies Involved
3.5.2 Canada
3.5.2.1 Cultivation
3.5.2.2 Production
3.5.2.3 Legal Status (CBD & THC)
3.5.2.4 Regulatory Bodies Involved
3.5.3 Germany
3.5.3.1 Cultivation/Production
3.5.3.2 Legal Status (CBD & THC)
3.5.3.3 Regulatory Bodies Involved
3.5.4 Italy
3.5.4.1 Cultivation
3.5.4.2 Production
3.5.4.3 Legal Status (CBD & THC)
3.5.4.4 Regulatory Bodies Involved
3.5.5 Croatia
3.5.5.1 Cultivation/Production
3.5.5.2 Legal Status (CBD & THC)
3.5.5.3 Regulatory Bodies Involved
3.5.6 Netherlands
3.5.6.1 Cultivation
3.5.6.2 Production
3.5.6.3 Legal Status (CBD & THC)
3.5.6.4 Regulatory Bodies Involved
3.5.7 Czech Republic
3.5.7.1 Cultivation/Production
3.5.7.2 Legal Status (CBD & THC)
3.5.8 Poland
3.5.8.1 Cultivation/Production
3.5.8.2 Legal Status (CBD & THC)
3.5.8.3 Regulatory Bodies Involved
3.5.9 Switzerland
3.5.9.1 Cultivation/Production
3.5.9.2 Legal Status (CBD & THC)
3.5.9.3 Regulatory Bodies Involved
3.5.10 Australia
3.5.10.1 Cultivation/Production
3.5.10.2 Legal Status (CBD & THC)
3.5.10.3 Regulatory Bodies Involved
3.5.11 Israel
3.5.11.1 Cultivation/Production
3.5.11.2 Legal Status (CBD & THC)
3.5.11.3 Regulatory Bodies Involved
3.5.12 Ururguay
3.5.12.1 Cultivation/Production
3.5.12.2 Legal Status (CBD & THC)
3.5.12.3 Regulatory Bodies Involved
3.5.13 Colombia
3.5.13.1 Cultivation/Production
3.5.13.2 Legal Status (CBD & THC)
3.5.13.3 Regulatory Bodies Involved
3.5.14 Argentina
3.5.14.1 Cultivation/Production
3.5.14.2 Legal Status (CBD & THC)
3.5.14.3 Regulatory Bodies Involved
3.5.15 Chile
3.5.15.1 Cultivation/Production
3.5.15.2 Legal Status (CBD & THC)
3.5.15.3 Regulatory Bodies Involved
3.6 Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Growing legalization of cannabis-based CBD products
3.6.1.2 Increasing preference toward cannabis extracts such as oils and tinctures
3.6.1.3 Growing adoption of CBD-based products for treating various medical conditions
3.6.1.4 Rise in the number of retailers selling CBD-based products
3.6.2 Market Restraint Analysis
3.6.2.1 Stringent government regulations
3.6.2.2 Absence of legalization programs in several Asian and African countries
3.6.2.3 High cost of CBD in leading markets
3.6.3 Industry Challenges
3.7 Cannabidiol (CBD) - Porter’s Analysis
3.7.1 Threat of New Entrants
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Bargaining Power of Suppliers
3.7.5 Threat of Substitutes
3.8 Cannabidiol (CBD) - PESTEL Analysis
3.8.1 Political
3.8.2 Environmental
3.8.3 Social
3.8.4 Technology
3.8.5 Legal
3.8.6 Economic
3.9 Opportunity Analysis
3.10 Import/Export Scenario, by Country
3.10.1 U.S.
3.10.2 Canada
3.10.2.1 Import
3.10.2.2 Export
3.10.3 Germany
3.10.4 Italy
3.10.5 France
3.10.6 Croatia
3.10.7 Netherlands
3.10.8 Czech Republic
3.10.9 Poland
3.10.10 Switzerland
3.10.11 Uruguay
3.10.12 Columbia
3.10.13 Brazil
3.10.14 Argentina
3.10.15 Chile
3.10.16 Australia
3.10.17 China
3.10.18 India
3.10.19 Japan
3.10.20 New Zealand
3.10.21 South Korea
3.10.22 South Africa
3.10.23 Israel
3.11 Product Adoption Pattern Analysis
3.12 Value Chain Analysis
3.12.1 Raw Material Trends
3.12.1.1 Market price evolution of biomass commodity cost (to processor)
3.12.1.2 Manufacturing Trends
3.13 Average Selling Price of Cannabidiol, by Country
3.14 Key End Users
3.14.1 U.S. Market Scenario
3.15 COVID-19 Impact Analysis
Chapter 4 Cannabidiol (CBD) Market: Source Type Estimates & Trend Analysis
4.1 Cannabidiol (CBD) Market Size & Forecasts And Trend Analysis By Source Type, 2017 - 2030, (USD Million)
4.1.1 Hemp
4.1.1.1 Hemp CBD market estimates and forecasts, 2017 - 2030 (USD Million)
4.1.2 Marijuana
4.1.2.1 Marijuana CBD market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 5 Cannabidiol (CBD) Market: Distribution Channel Estimates & Trend Analysis
5.1 Cannabidiol (CBD) Market, By Distribution Channel Analysis
5.2 Business to Business (B2B)
5.2.1 Business to Business (B2B) market estimates and forecasts, 2017 - 2030 (USD Million)
5.3 Business to Consumer (B2C)
5.3.1 Hospital Pharmacies
5.3.1.1 Hospital pharmacies market estimates and forecasts, 2017 - 2030 (USD Million)
5.3.2 Online Stores
5.3.2.1 Online market estimates and forecasts, 2017 - 2030 (USD Million)
5.3.3 Retail Stores
5.3.3.1 Retail stores market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 6 Cannabidiol (CBD) Market: End-use Estimates & Trend Analysis
6.1 Cannabidiol (CBD) Market, By End-use Analysis
6.2 Medical
6.2.1 Chronic Pain
6.2.1.1 Chronic pain market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.2 Mental Disorders
6.2.2.1 Mental disorders market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.3 Cancer
6.2.3.1 Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.4 Others
6.2.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
6.3 Personal Use
6.3.1 Personal Use market estimates and forecasts, 2017 - 2030 (USD Million)
6.4 Pharmaceutical
6.4.1 Pharmaceutical CBD market estimates and forecasts, 2017 - 2030 (USD Million)
6.5 Wellness
6.5.1 Food & Beverages
6.5.1.1 Food & beverages market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.2 Personal Care & Cosmetics
6.5.2.1 Personal care & cosmetics market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.3 Nutraceuticals
6.5.3.1 Nutraceuticals market estimates and forecasts, 2017 - 2030 (USD Million)
6.5.4 Others
6.5.4.1 Other end-use market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 7 Cannabidiol (CBD) Market: Regional Estimates & Trend Analysis
7.1 Global Cannabidiol Market Share, By Region, 2021 & 2030
7.2 North America
7.2.1 U.S.
7.2.1.1 U.S. CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.2.2 Canada
7.2.2.1 Canada CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3 Europe
7.3.1 U.K.
7.3.1.1 U.K. CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.2 Germany
7.3.2.1 Germany CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.3 France
7.3.3.1 France CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.4 Italy
7.3.4.1 Italy CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.5 Netherlands
7.3.5.1 Netherlands CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.6 Croatia
7.3.6.1 Croatia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.7 Poland
7.3.7.1 Poland CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.8 Czech Republic
7.3.8.1 Czech Republic CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.9 Switzerland
7.3.9.1 Switzerland CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Australia
7.4.1.1 Australia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China CBD Market market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.3 India
7.4.3.1 India CBD Market market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.5 New Zealand
7.4.5.1 New Zealand CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5 Latin America
7.5.1 Brazil
7.5.1.1 Brazil CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.2 Argentina
7.5.2.1 Argentina CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.3 Colombia
7.5.3.1 Colombia CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.4 Mexico
7.5.4.1 Mexico CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.5 Uruguay
7.5.5.1 Uruguay CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.5.6 Chile
7.5.6.1 Chile CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.6 MEA
7.6.1 South Africa
7.6.1.1 South Africa CBD market estimates and forecasts, 2017 - 2030 (USD Million)
7.6.2 Israel
7.6.2.1 Israel CBD market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Company Profiles (Cannabis Companies)
8.1.1 Canopy Growth Corporation.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.2 Product Benchmarking
8.1.2.1 Strategic Initiatives
8.1.3 Aphria, Inc.
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 Aurora Cannabis
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Strategic initiatives
8.1.5 Maricann, Inc. (Wayland Group Corporation)
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Business strategies
8.1.6 Tilray
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Strategic Initiatives
8.1.7 GW Pharmaceuticals, plc
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Strategic Initiatives
8.1.8 ABcann Medicinals, Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Strategic Initiatives
8.1.9 Organigram Holding, Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Strategic Initiatives
8.1.10 Tikun Olam
8.1.10.1 Company overview
8.1.10.2 Strategic Initiatives
8.1.11 The Cronos Group
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Strategic Initiatives
8.2 Company Profiles (Cannabidiol Companies)
8.2.1 ENDOCA
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Isodiol International, Inc.
8.2.2.1 Company overview
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.3 MEDICAL MARIJUANA, INC.
8.2.3.1 company overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 Cannoid, LLC
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.5 Elixinol
8.2.5.1 Company Overview
8.2.5.2 Product Benchmarking
8.2.5.3 Strategic Initiatives
8.2.6 Folium Biosciences
8.2.6.1 Company Overview
8.2.6.2 Product Benchmarking
8.2.6.3 Strategic Initiatives
8.2.7 NuLeaf Naturals, LLC
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Pharmahemp d.o.o.
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(通信回線)の最新刊レポート

Grand View Research社の通信回線分野での最新刊レポート

本レポートと同じKEY WORD(cannabidiol)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る